Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE) (SCD-CARRE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04084080|
Recruitment Status : Recruiting
First Posted : September 10, 2019
Last Update Posted : April 19, 2021
|Condition or disease||Intervention/treatment||Phase|
|Sickle Cell Disease||Biological: Red Blood Cell Other: Standard of care||Phase 3|
As patients with sickle cell disease (SCD) live to adulthood, the chronic impact of sustained hemolytic anemia and episodic vaso-occlusive events take their toll, with the progressive development of cardiopulmonary organ dysfunction. This culminates in the development of pulmonary hypertension, left ventricular diastolic heart disease, dysrhythmia, chronic kidney disease and sudden death, all major cardiovascular complications of SCD for which there are no approved or consensus therapies. The risk of having pulmonary hypertension and diastolic heart disease can be non-invasively assessed by laboratory tests (NT-proBNP) and Doppler-echocardiography (estimated pulmonary artery systolic pressure). A recent meta-analysis of approximately 6000 patients with SCD demonstrated that patients with elevated tricuspid regurgitant jet velocity (TRV), which is an Doppler-echocardiographic measurement that estimates the pulmonary artery systolic pressure, walked an estimated 30.4 meters less in a 6 minute walk test than those without elevated TRV, and elevated TRV was associated with high mortality (hazard ratio of 4.9). In two large registry cohorts of adult patients with SCD, the investigators found that approximately 20% of the adult SCD population have high values for both biomarkers, defined as a TRV ≥ 2.5 meters per second AND a NT-proBNP ≥ 160 pg/mL, and that the 12-month mortality rate is 7.9% in this group as compared to 0.5% in patients with normal TRV or NT-proBNP values, with a risk ratio for hospitalization of 1.6. This suggests that a simple screening profile of TRV and NT-proBNP can identify about 20% of patients with SCD at the highest risk of death and hospitalization.
Given the increased mortality and early loss of functional capacity associated with cardiovascular disease in SCD adults, it is important to test effective therapeutic interventions in such patients. Red blood cell transfusions are administered by either simple or exchange transfusion, the latter removes the patients blood and replaces it with transfused red blood cells. Exchange transfusions have proven effective for acute treatment of almost all SCD complications, including severe acute chest syndrome, stroke, splenic or hepatic sequestration, and multi-organ failure, and are also used chronically for stroke prevention and recurrent acute chest syndrome. In this study the investigators hypothesize that monthly exchange transfusion will limit disease progression, improve exercise capacity, and prevent interval episodes of vaso-occlusive painful crisis and the acute chest syndrome that acutely increases pulmonary pressures and cause right heart failure.
The investigators propose to perform a clinical trial to evaluate the effects of automated exchange blood transfusion on patient morbidity and mortality, compared to standard of care among 150 adult high risk SCD patients. The trial will leverage existing coordinating center infrastructure at the University of Pittsburgh and will involve 22 experienced clinical sites. Despite the safety and wide utilization of erythrocytapheresis in adult patients with SCD, there is no consensus or quality efficacy data on its use to improve outcomes in our aging high-risk SCD patients with progressive end-organ dysfunction.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)|
|Actual Study Start Date :||February 26, 2020|
|Estimated Primary Completion Date :||December 31, 2025|
|Estimated Study Completion Date :||April 30, 2026|
Experimental: Exchange transfusion plus standard of care
Randomized to standard of care and automated exchange blood transfusion every 3-6 weeks for 12 months.
Biological: Red Blood Cell
Red blood cell exchange transfusions will be performed every 3-6 weeks to maintain a target post-transfusion hemoglobin S level of <20% and a pre-transfusion hemoglobin S of <30%.
Other Name: Red blood cell (RBC)
Other: Standard of care
NHLBI/ASH/ATS Expert Panel recommended guidelines
Active Comparator: Standard of care
Randomized to standard of care
Other: Standard of care
NHLBI/ASH/ATS Expert Panel recommended guidelines
- Episodes of clinical worsening [ Time Frame: 12 months ]The efficacy of the intervention will be measured by comparing the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/Hospital visits) or resulting in death over 12 months between groups.
- Acute healthcare event [ Time Frame: 12 months ]A 6-level prioritized rank-based outcome involving death and acute health care encounters with evidence of cor pulmonale, stroke, liver failure, acute kidney injury, or the acute chest syndrome during the 12 months of treatment and follow-up. 1.No death or SCD-related acute health care encounters within 12 months; 2.SCD-related acute health care encounter but NO major complications (acute kidney injury (AKI), acute chest syndrome (ACS), cor pulmonale, stroke, liver failure) or death within 12 months; 3.SCD-related acute health care encounter with 1 major complication (AKI, ACS, cor pulmonale, stroke, or liver failure) but no death within 12 months. 4.SCD-related acute health care encounter with 2 major complications (AKI, ACS, cor pulmonale, stroke, or liver failure) but no death within 12 months; 5.SCD-related acute health care encounter with 3 or more major complications (AKI, ACS, cor pulmonale, stroke, or liver failure) but no death within 12 months; 6.Death within 12 months.
- Twelve-month survival [ Time Frame: 12 months ]Survival over twelve-month period will be analyzed and compared between the group receiving the intervention and the group receiving care routinely provided for sickle cell patients based on the NHLBI guidelines.
- Survival free of acute healthcare encounters [ Time Frame: 12 months ]Survival free of acute health care encounters over 12 months.
- Total number of acute health care encounters [ Time Frame: 12 months ]The total number of acute health care encounters (non-elective infusion center/ER/Hospital visits) with evidence of cor pulmonale (physical exam findings, NT-proBNP increase plus echocardiographic evidence of worsening right heart function).
- Measures of exercise capacity - 6 minute walk distance [ Time Frame: 4, 8, and 12 months ]Measures of exercise capacity assessed at 4, 8 and 12 months by the distance walked in the six minute walk distance assessment
- Measures of exercise capacity - outpatient activity [ Time Frame: 4, 8, and 12 months ]Measures of exercise capacity assessed at 4, 8 and 12 months by the distance walked in a 7 day in the outpatient setting.
- Cardiovascular risk [ Time Frame: 12 months ]
Established cardiovascular risk biomarkers and indices are combined to help the investigators form an opinion about cardiovascular risks. The following will be measured: NT-proBNP, QT prolongation, systemic pulse pressure, albuminuria, estimated GFR and CKD progression Kidney Disease:
Improving Global Outcomes (KDIGO) CKD Work Group criteria.
- Development of new leg ulcers [ Time Frame: 4, 8 and 12 months ]Participants will be assessed for development of new leg ulcers at each physical exam.
- Measures of exercise capacity - WHO Classification [ Time Frame: 4, 8 and 12 months ]WHO functional status severity will be measured assessing by looking at limitation of usual physical activity from I (no limitation in usual physical activity) to Class IV (inability to perform any physical activity at rest)
- Nocturnal desaturation [ Time Frame: 4, 8 and 12 months ]Nocturnal desaturation will measured using a wearable device to measure blood oxygen saturation for 7 nights at home.
- SCD specific patient reported outcomes - Pain [ Time Frame: 4, 8 and 12 months ]SCD specific patient reported outcomes as measured by self-reported pain
- SCD specific patient reported outcomes -Quality of Life modified PROMIS scale [ Time Frame: 4, 8 and 12 months ]SCD specific patient reported outcomes as measured by a modified version of health related quality of life questionnaire from PROMIS QoL measure
- SCD specific patient reported outcomes -Quality of Life modified ASCQ-Me scale [ Time Frame: 4, 8 and 12 months ]SCD specific patient reported outcomes as measured by a modified version of health related quality of life questionnaire from ASCQ-Me QoL measure
- Cardiovascular function by echocardiography - TRjv [ Time Frame: 4, 8 and 12 months ]Cardiovascular function measures from echocardiography assessed at 4, 8 and 12 months: echocardiographic measures of tricuspid regurgitant jet velocity in m/s.
- Cardiovascular function by echocardiography - diastolic left heart function - E/A ratio [ Time Frame: 4, 8 and 12 months ]Diastolic left heart function measured by E/A ratio will be assessed by echocardiography.
- Cardiovascular function by echocardiography - diastolic left heart function - E/Em ratio [ Time Frame: 4, 8 and 12 months ]Diastolic left heart function measured by E/Em ratio will be assessed by echocardiography.
- Cardiovascular function by echocardiography - diastolic left heart function - deceleration time [ Time Frame: 4, 8 and 12 months ]Diastolic left heart function measured by deceleration time will be assessed by echocardiography.
- Cardiovascular function by echocardiography - systolic right heart function -E/Em ratio [ Time Frame: 4, 8 and 12 months ]Systolic right heart health will be measured by assessing right ventricular size from echocardiography of the heart
- Cardiovascular function by echocardiography - systolic right heart function - ventricular contractility [ Time Frame: 4, 8 and 12 months ]Systolic right heart health will be measured by assessing right ventricular contractility from echocardiography of the heart
- Cardiovascular function by echocardiography - systolic right heart function - TAPSE [ Time Frame: 4, 8 and 12 months ]Systolic right heart health will be measured by assessing tricuspid annular plane systolic excursion (TAPSE).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04084080
|Contact: Jude Jonassaint, RNfirstname.lastname@example.org|
|Contact: Nydia Chien, MSNemail@example.com|
|United States, Alabama|
|University of Alabama||Recruiting|
|Tuscaloosa, Alabama, United States, 35401|
|Contact: Sarah Moderhack 205-975-6215 firstname.lastname@example.org|
|Principal Investigator: Julie Kanter, MD|
|United States, California|
|UCSF Benioff Children's Hospital Oakland||Recruiting|
|Oakland, California, United States, 94609|
|Contact: Robert Hagar, MD 510-428-3168 email@example.com|
|Principal Investigator: Robert Hagar, MD|
|United States, Georgia|
|Atlanta, Georgia, United States, 30322|
|Contact: Morgan McMemore, MD 414-712-8895 SCDresearch@emory.edu|
|Principal Investigator: Morgan McLemore, MD|
|United States, Illinois|
|University of Illinois at Chicago||Recruiting|
|Chicago, Illinois, United States, 60607|
|Contact: Taif Hassan 312-996-9052 firstname.lastname@example.org|
|Principal Investigator: Sally Campbell-Lee, MD|
|Principal Investigator: Victor Gordeuk, MD|
|United States, Maryland|
|Johns Hopkins University||Recruiting|
|Baltimore, Maryland, United States, 21206|
|Contact: Rosie Kopp 443-287-2889 email@example.com|
|Principal Investigator: S. Lanzkron, MD|
|United States, Massachusetts|
|Boston Medical Center||Recruiting|
|Boston, Massachusetts, United States, 02118|
|Contact: Elizabeth Klings, MD 617-358-1226 firstname.lastname@example.org|
|Principal Investigator: Elizabeth S Klings, MD|
|United States, Missouri|
|Washington University-St. Louis||Recruiting|
|Saint Louis, Missouri, United States, 63110|
|Contact: Allison King, MD 314-454-4291 King_a@wustl.edu|
|Principal Investigator: Allison King, MD|
|United States, New York|
|Icahn School of Medicine at Mount Sinai||Recruiting|
|New York, New York, United States, 10029|
|Contact: Jeffrey Glassberg, MD 212-824-8506 Jeffrey.email@example.com|
|Principal Investigator: Jeffrey Glassberg, MD|
|United States, North Carolina|
|Charlotte, North Carolina, United States, 28204|
|Contact: Padjama Veeramreddy, MD 980-422-2398 Padmaja.Veeramreddy@atriumhealth.org|
|Principal Investigator: Padjama Veeramreddy, MD|
|Durham, North Carolina, United States, 27708|
|Contact: Marilyn Telen, MD 919-684-5378 firstname.lastname@example.org|
|Principal Investigator: Marilyn J Telen, MD|
|East Carolina University||Recruiting|
|Greenville, North Carolina, United States, 27834|
|Contact: Darla Lilles, MD 252-744-1720 LILLESD@ecu.edu|
|Principal Investigator: Darla Lilles, MD|
|United States, Ohio|
|Ohio State University||Recruiting|
|Columbus, Ohio, United States, 43210|
|Contact: Kristina Landes 614-366-8445 email@example.com|
|Principal Investigator: Payal Desai, MD|
|United States, Pennsylvania|
|University of Pittsburgh Medical Center||Recruiting|
|Pittsburgh, Pennsylvania, United States, 15232|
|Contact: Jude Jonassaint, RN jonassaintjc@Upmc.edu|
|Principal Investigator: Enrico M Novelli, MD|
|United States, Texas|
|University of Texas Health Science Center at Houston||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: Angelica Rodriguez 713-500-6544 firstname.lastname@example.org|
|Principal Investigator: Modupe Idowu, MD|
|United States, Virginia|
|Virginia Commonwealth University||Recruiting|
|Richmond, Virginia, United States, 23284|
|Contact: Daniel Sop 804-828-0810 email@example.com|
|Principal Investigator: Wally Smith, MD|
|Principal Investigator:||Mark Gladwin, MD||University of Pittsburgh|
|Principal Investigator:||Darrell Triulzi, MD||University of Pittsburgh|
|Principal Investigator:||Maria Brooks, PhD||University of Pittsburgh|